Effect of different buffers on the biocompatibility of CAPD solutions.
Commercially available solutions for continuous ambulatory peritoneal dialysis (CAPD) affect the viability and function of the cells in the peritoneal cavity. The low biocompatibility of the solutions may be caused by a low pH, hyperosmolality, high glucose content, and lack of potassium, glutamine, and other components essential for normal cellular functions. The nature of the buffer employed is also important for the cytotoxicity of the solutions. Lactate, the most frequently used buffer, has been shown to inhibit cellular functions important for the peritoneal defense system including phagocytosis, bacterial killing, and secretion of cytokines. It is generally believed that the cytotoxicity of lactate is caused by lowering of intracellular pH and impairment of metabolism due to changed redox potentials. However, the cytotoxicity of lactate is highly dependent upon the pH of the solutions, indicating that passive or active diffusion across the cell membrane is determining the effects of lactate. Bicarbonate has been heavily advocated as an alternative buffer because it is the most important naturally occurring buffer in plasma and it enables a pH of approximately 7.4 in the solutions. However, due to sedimentation of calcium carbonate (CaCO3) and production of toxic glucose metabolites it is difficult to prepare and store bicarbonate-based solutions. Moreover, investigations have revealed that even bicarbonate-based solutions are not optimal regarding biocompatibility, presumably due to a paradoxical intracellular acidification caused by influx of carbon dioxide (CO2). More recently, the effect of other buffers such as pyruvate and histidine have been examined. Especially pyruvate is a promising new buffer candidate.
Schambye
H T
HT
Department of Nephrology, Odense University Hospital, Denmark.
D000136:Acid-Base Equilibrium / Q000187:drug effects* / Q000502:physiology; D001639:Bicarbonates / Q000008:administration & dosage / Q000009:adverse effects; D002021:Buffers; D002455:Cell Division / Q000187:drug effects* / Q000502:physiology; D002470:Cell Survival / Q000187:drug effects* / Q000502:physiology; D015314:Dialysis Solutions / Q000008:administration & dosage / Q000009:adverse effects*; D006639:Histidine / Q000008:administration & dosage / Q000009:adverse effects; D006801:Humans; D006863:Hydrogen-Ion Concentration; D007676:Kidney Failure, Chronic / Q000503:physiopathology / Q000628:therapy*; D007773:Lactates / Q000008:administration & dosage / Q000009:adverse effects; D019344:Lactic Acid; D010531:Peritoneal Dialysis, Continuous Ambulatory; D010537:Peritoneum / Q000187:drug effects / Q000503:physiopathology; D011773:Pyruvates / Q000008:administration & dosage / Q000009:adverse effects; D019289:Pyruvic Acid
D001639:Bicarbonates; D002021:Buffers; D015314:Dialysis Solutions; D007773:Lactates; D011773:Pyruvates; D019344:Lactic Acid; D006639:Histidine; D019289:Pyruvic Acid